Company Of The Day: Merck

+7.12%
Upside
92.42
Market
99.00
Trefis
MRK: Merck logo
MRK
Merck

What?

Merck (NYSE:MRK) and AstraZenica’s cancer drug Lynparza has been approved by the U.S. FDA to treat patients with early-stage breast cancer with certain mutations.

So What?

Relevant Articles
  1. Is There A Better Pick Over Merck Stock In Animal Health Space?
  2. Will Merck Stock Rise After Its Q1 Results?
  3. What’s Next For Merck Stock After A 6% Fall In A Month?
  4. Will Merck Stock Rise After Its Q4 Results?
  5. Here’s A Better Pharmaceutical Pick Over Merck Stock
  6. What’s Next For Merck Stock After FDA Advisors Back Its Covid-19 Pill?

Merck’s alliance revenue from Lynparza stood at about $989 million in 2021, growing 36% year-over-year, making it one of the company’s fastest-growing drugs. It’s likely that the new approval could increase sales further.

See Our Complete Analysis For Merck

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Mar 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 MRK Return 2% 2% 33%
 S&P 500 Return -4% -12% 88%
 Trefis MS Portfolio Return -4% -14% 238%

[1] Month-to-date and year-to-date as of 3/14/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates